Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Can-Fite BioPharma ( (CANF) ).
On May 13, 2026, Can-Fite BioPharma announced that, following positive interim results from its ongoing Phase 2a trial in advanced pancreatic adenocarcinoma, it plans to advance its oral A3 adenosine receptor agonist Namodenoson into a Phase 2b study in combination with immunotherapy. The Phase 2a data showed a favorable safety profile, extended treatment beyond 16 months in some patients, stable disease in more than 30% of evaluable patients, and 35% of patients remaining on therapy and follow-up.
The planned Phase 2b trial will further evaluate Namodenoson plus immunotherapy in advanced pancreatic cancer, focusing on progression-free survival, overall survival, disease stabilization and other efficacy endpoints. Can-Fite also intends to present details of the Phase 2b study design at the BIO International Convention in San Diego as it deepens partnership talks with major oncology companies, leveraging Namodenoson’s orphan drug status for pancreatic cancer and its existing Phase III and Phase 2 programs in liver disease to strengthen its oncology and liver franchise.
The most recent analyst rating on (CANF) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (declining revenue, ongoing losses, and persistent cash burn) and bearish technical signals (price below key moving averages with negative MACD). Low leverage provides some risk mitigation, but valuation is not supportive given losses and no dividend data.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an advanced clinical-stage biotechnology company developing oral small-molecule drugs targeting the A3 adenosine receptor for cancer, liver and inflammatory diseases, addressing multi-billion-dollar markets. Its lead candidates include Piclidenoson for psoriasis, Namodenoson for hepatocellular carcinoma, MASH and pancreatic cancer, and CF602 for erectile dysfunction, all of which have shown favorable safety across more than 1,600 patients.
Average Trading Volume: 1,183,330
Technical Sentiment Signal: Sell
Current Market Cap: $7.07M
See more data about CANF stock on TipRanks’ Stock Analysis page.